BioTech Medics, Inc. Announces Significant Finding Treating Diabetic Patients
11 11월 2005 - 3:31AM
PR Newswire (US)
DALLAS, Nov. 10 /PRNewswire-FirstCall/ -- Charles R. Crane, MD,
President & Medical Director of BioTech Medics, Inc., (OTC Pink
Sheets: BTMD) announced today a significant finding while treating
neuropathic pain in diabetic patients with the NeuroLase (TM)
therapeutic medical laser. "Over 25 diabetic patients have been
successfully treated with the Neurolase (TM) Medical Laser in
Dallas over the past 2 years for painful diabetic peripheral
neuropathy, using the BioTech L3aser(TM) proprietary Protocols.
Most patients had previously been treated with narcotics,
antidepressants and anticonvulsants without lasting improvement.
Using the non-invasive, drug-free Neurolase (TM) Medical Laser
these patients were able to achieve significant lasting pain
relief. These patients were also experiencing problems with glucose
control even with injections of insulin. Blood glucose levels in
excess of 300 were not uncommon," said Dr. Crane. "In follow-up
visits, we have discovered that within 24 hours of laser treatment,
patients experienced a substantial decrease in blood sugar with
glucose readings below 150 and predictable control. Decreased
medication usage was also noted. Several of the patients who have
had bi-weekly laser treatments for pain management over 6 months,
consistently had blood sugar readings in the normal range." BioTech
Medics has sent a letter to the World Association of Laser Therapy
(WALT) of which BTMD is a member, concerning this finding and is
seeking medical research grants for a clinical study. There are
over 18 million Americans who have diabetes, according to the ADA,
with an estimated 5 million experiencing painful neuropathy.
BioTech Medics operates a Pain Management & Wellness Center in
Dallas; is a distributor for the NeuroLase Therapeutic Medical
Laser. The company plans on 100 or more centers nationwide. Dr.
Crane is a Texas and Tennessee licensed medical doctor with board
certification in Physical Medicine & Rehabilitation with
specialization in non-invasive pain management. Safe Harbor for
Forward-Looking Statements. This press release may contain
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995 (the "Act"). In
Particular, when used, the words "plan," "confident that,"
"believe," "scheduled," "expect," or "intend to," and similar
conditional expressions are intended to identify forward-looking
statements within the meaning of the Act and are subject to the
safe harbor created by the Act. Such statements are subject to
certain risks and uncertainties and actual results could differ
materially from those expressed in any of the forward-looking
statements. Keith Houser, CEO of BioTech Medics, +1-972-274-5533
DATASOURCE: BioTech Medics, Inc. CONTACT: Keith Houser, CEO of
BioTech Medics, Inc., +1-972-274-5533 Web site:
http://www.biotechmedics.com/
Copyright